Fisher Asset Management LLC decreased its position in Sanofi (NYSE:SNY) by 8.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,443,197 shares of the company’s stock after selling 1,194,986 shares during the period. Fisher Asset Management LLC owned 0.48% of Sanofi worth $475,206,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Bessemer Group Inc. increased its stake in Sanofi by 77.1% in the second quarter. Bessemer Group Inc. now owns 3,445 shares of the company’s stock worth $144,000 after buying an additional 1,500 shares during the period. Signaturefd LLC increased its stake in Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock worth $146,000 after buying an additional 490 shares during the period. JFS Wealth Advisors LLC increased its stake in Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock worth $166,000 after buying an additional 134 shares during the period. Bradley Foster & Sargent Inc. CT purchased a new stake in Sanofi during the second quarter worth $205,000. Finally, Weik Investment Services Inc. purchased a new stake in Sanofi during the second quarter worth $222,000. 9.58% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Shares of Sanofi (NYSE:SNY) traded up 0.32% on Monday, hitting $40.16. The stock had a trading volume of 1,171,528 shares. The company has a 50 day moving average of $39.01 and a 200-day moving average of $39.82. The firm has a market capitalization of $103.37 billion, a P/E ratio of 22.64 and a beta of 0.97. Sanofi has a 12-month low of $36.81 and a 12-month high of $44.76.

A number of research firms recently weighed in on SNY. Zacks Investment Research raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, October 27th. Leerink Swann reaffirmed a “buy” rating on shares of Sanofi in a report on Monday, September 26th. Goldman Sachs Group Inc. initiated coverage on Sanofi in a report on Monday, November 7th. They set a “neutral” rating on the stock. Jefferies Group reaffirmed a “hold” rating on shares of Sanofi in a report on Wednesday, September 14th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Sanofi in a report on Thursday, September 15th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $60.50.

Sanofi Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

5 Day Chart for NYSE:SNY

Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.